You are here
European Association of Urology Guidelines for Clear Cell Renal Cancers That Are Resistant to Vascular Endothelial Growth Factor Receptor–Targeted Therapy
Keywords: Nivolumab, Cabozantinib, Renal cancer, Guidelines, European Association of Urology.
a The Royal Free NHS Trust and Barts Cancer Institute, Queen Mary University of London, London, UK
b Department of Urology, Ludwig-Maximilians University, Munich, Germany
c Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden
d Department of Urology, University of Rennes, Rennes, France
e Division of Urology, University of Texas Medical School at Houston, Houston, TX, USA
f Department of Urology, Skåne University Hospital, Malmö, Sweden
g Patient Advocate International Kidney Cancer Coalition (IKCC), University Medical Centre Utrecht, Nephrology Department, Utrecht, The Netherlands
h Department of Urology, Sunderby Hospital, Sunderby, Sweden
i Department of Urology, Faculty Hospital and Faculty of Medicine in Pilsen, Charles University in Prague, Prague, Czech Republic
j Department of Urology and Urologic Oncology, Hannover Medical School, Hannover, Germany
k Academic Urology Unit, University of Aberdeen, Aberdeen, UK
l Department of Urology, Coimbra University Hospital, Coimbra, Portugal
m Department of Urology, University Hospital Schleswig-Holstein, Lübeck, Germany
n Division of Urology, Maggiore della Carità Hospital, University of Eastern Piedmont, Novara, Italy
o Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
⁎ Corresponding author. The Royal Free NHS Trust and Barts Cancer Institute, Queen Mary University of London, London EC1A7BE, UK. Tel. +44 793 204 81 09; Fax: +44 207 601 85 22.
© 2016 European Association of Urology, Published by Elsevier B.V.